Search
Now showing items 231-240 of 288
CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in Cancer.
(CELL PRESS, 2017-07-26)
Genes whose function is selectively essential in the presence of cancer-associated genetic aberrations represent promising targets for the development of precision therapeutics. Here, we present CancerGD, a resource that ...
Application of Liquid Biopsies in Cancer Targeted Therapy.
(WILEY, 2017-11-01)
As a growing body of evidence demonstrates intertumoral and intratumoral heterogeneity and clonal evolution, both during carcinogenesis and also throughout treatment resulting in acquired drug resistance, the utility of ...
Quantitative phosphoproteomic analysis of acquired cancer drug resistance to pazopanib and dasatinib.
(ELSEVIER SCIENCE BV, 2018-01-06)
UNLABELLED: Acquired drug resistance impacts the majority of patients being treated with tyrosine kinase inhibitors (TKIs) and remains a key challenge in modern anti-cancer therapy. The lack of clinically effective therapies ...
Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface.
(NATURE PUBLISHING GROUP, 2017-04-18)
Lysyl oxidase (LOX) remodels the tumour microenvironment by cross-linking the extracellular matrix. LOX overexpression is associated with poor cancer outcomes. Here, we find that LOX regulates the epidermal growth factor ...
Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?
(BENTHAM SCIENCE PUBL LTD, 2018-01-01)
The efficacy of cancer immunotherapy relies on the ability of the host immune system to recognise the cancer as non-self and eliminate it from the body. Whilst this is an extremely fertile area of medical research, with ...
AKT Inhibition in Solid Tumors With AKT1 Mutations.
(AMER SOC CLINICAL ONCOLOGY, 2017-07-10)
Purpose AKT1 E17K mutations are oncogenic and occur in many cancers at a low prevalence. We performed a multihistology basket study of AZD5363, an ATP-competitive pan-AKT kinase inhibitor, to determine the preliminary ...
Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study.
(ENDOCRINE SOC, 2017-05-01)
CONTEXT: Growth hormone (GH) is prescribed for an increasing range of indications, but there has been concern that it might raise cancer risk. Published data are limited. OBJECTIVE: To examine cancer risks in relation to ...
Combine and conquer: challenges for targeted therapy combinations in early phase trials.
(NATURE PUBLISHING GROUP, 2017-01-01)
Our increasing understanding of cancer biology has led to the development of molecularly targeted anticancer drugs. The full potential of these agents has not, however, been realised, owing to the presence of de novo ...
Empowerment in adolescents and young adults with cancer: Relationship with health-related quality of life.
(WILEY, 2017-10-15)
BACKGROUND: The difficulties adolescents and young adults (AYAs) encounter during a cancer experience may result in a reduction in or absence of empowerment. The aims of the current study were to assess levels of empowerment ...
Young adults: a unique group in cancer epidemiological research.
(ELSEVIER SCIENCE INC, 2018-02-01)